Table 3.
| Study week | Eosinophilia grade | SOLO 1 & 2, n (%)b | CHRONOS, n (%) | ||||
|---|---|---|---|---|---|---|---|
| Placebo qw (n = 456) | Dupilumab 300 mg q2w (n = 465) | Dupilumab 300 mg qw (n = 455) | Placebo qw + TCS (n = 315) | Dupilumab 300 mg q2w + TCS (n = 110) | Dupilumab 300 mg qw + TCS (n = 315) | ||
| 0 | 1 | 109 (23·9) | 111 (23·9) | 131 (28·8) | 90 (28·6) | 29 (26·4) | 57 (18·1) |
| 2 | 29 (6·4) | 28 (6·0) | 25 (5·5) | 12 (3·8) | 2 (1·8) | 13 (4·1) | |
| 3 | 1 (0·2) | 0 | 0 | 0 | 1 (0·9) | 1 (0·3) | |
| 4 | 1 | 104 (22·8) | 113 (24·3) | 102 (22·4) | 51 (16·2) | 16 (14·5) | 42 (13·3) |
| 2 | 29 (6·4) | 39 (8·4) | 48 (10·5) | 6 (1·9) | 2 (1·8) | 13 (4·1) | |
| 3 | 0 | 3 (0·6) | 2 (0·4) | 0 | 1 (0·9) | 0 | |
| 8 | 1 | 79 (17·3) | 92 (19·8) | 105 (23·1) | 47 (14·9) | 21 (19·1) | 45 (14·3) |
| 2 | 19 (4·2) | 45 (9·7) | 39 (8·6) | 1 (0·3) | 3 (2·7) | 14 (4·4) | |
| 3 | 0 | 1 (0·2) | 3 (0·7) | 0 | 1 (0·9) | 0 | |
| 12 | 1 | 84 (18·4) | 86 (18·5) | 95 (20·9) | 34 (10·8) | 19 (17·3) | 53 (16·8) |
| 2 | 14 (3·1) | 43 (9·2) | 40 (8·8) | 3 (1·0) | 4 (3·6) | 7 (2·2) | |
| 3 | 0 | 0 | 1 (0·2) | 0 | 0 | 0 | |
| 16 | 1 | 81 (17·8) | 99 (21·3) | 91 (20·0) | 44 (14·0) | 22 (20·0) | 49 (15·6) |
| 2 | 11 (2·4) | 33 (7·1) | 35 (7·7) | 3 (1·0) | 4 (3·6) | 7 (2·2) | |
| 3 | 0 | 2 (0·4) | 1 (0·2) | 0 | 0 | 0 | |
| 20 | 1 | – | – | – | 27 (8·6) | 20 (18·2) | 37 (11·7) |
| 2 | – | – | – | 3 (1·0) | 3 (2·7) | 5 (1·6) | |
| 3 | – | – | – | 0 | 1 (0·9) | 1 (0·3) | |
| 28 | 1 | – | – | – | 32 (10·2) | 14 (12·7) | 37 (11·7) |
| 2 | – | – | – | 3 (1·0) | 4 (3·6) | 8 (2·5) | |
| 3 | – | – | – | 0 | 0 | 1 (0·3) | |
| 36 | 1 | – | – | – | 29 (9·2) | 18 (16·4) | 42 (13·3) |
| 2 | – | – | – | 2 (0·6) | 3 (2·7) | 2 (0·6) | |
| 3 | – | – | – | 0 | 0 | 0 | |
| 44 | 1 | – | – | – | 29 (9·2) | 17 (15·5) | 33 (10·5) |
| 2 | – | – | – | 1 (0·3) | 1 (0·9) | 5 (1·6) | |
| 3 | – | – | – | 0 | 0 | 0 | |
| 52 | 1 | – | – | – | 28 (8·9) | 15 (13·6) | 29 (9·2) |
| 2 | – | – | – | 1 (0·3) | 3 (2·7) | 5 (1·6) | |
| 3 | – | – | – | 0 | 0 | 0 | |
a
The eosinophilia grade scale follows the guidance provided by the U.S. Food and Drug Administration:37 grade 1: eosinophil counts of 0·65–1·5 × 109 L−1; grade 2: 1·501–5·0 × 109 L−1; grade 3: > 5·0 × 109 L−1.
Post‐16 week data were not collected for SOLO; qw, once weekly; q2w, every 2 weeks; TCS, topical corticosteroids.